Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Dent Neurologic Institute

Neither a doctor nor a teaching hospital

Research payments

$793,414

177 payments

Through program year 2025, Dent Neurologic Institute is reported as receiving $793,414 in research payments, across 177 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $213,870 12
2024 Research $19,920 7
2023 Research $26,636 5
2022 Research $75,631 5
2021 Research $7,185 21
2020 Research $161,400 70
2019 Research $288,772 57

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eisai Inc. $199,632 96 payments
  2. E.R. Squibb & Sons, L.L.C. $182,527 4 payments
  3. Amgen Inc. $137,559 11 payments
  4. Novartis Pharmaceuticals Corporation $96,534 9 payments
  5. Teva Pharmaceuticals USA, Inc. $64,600 1 payment
  6. Avanir Pharmaceuticals, Inc. $44,644 12 payments
  7. AbbVie, Inc. $32,084 12 payments
  8. TerSera Therapeutics LLC $10,000 2 payments
  9. Ipsen Innovation $8,050 2 payments
  10. ACADIA Pharmaceuticals Inc $5,500 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $177,119 2 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $149,618 75 payments
  3. P1b study in children and adolescents with migraine $117,364 2 payments
  4. US Real World Clinical Effectiveness of Concomitant Use of Gepants with Fremanezumab migraine patients: a retrospective chart review study $64,600 1 payment
  5. A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate Or Fingolimod Therapy $32,393 2 payments
  6. A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $28,724 1 payment
  7. A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase $28,672 2 payments
  8. 17-Avp-825-301 $22,559 3 payments
  9. A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $21,290 20 payments
  10. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $20,149 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record